Resistance to endocrine therapies remains a major challenge for the successful 18 management of patients with estrogen receptor-positive (ER+) breast cancers. Central to 19 the development of resistance is the adaptive reprogramming of cellular metabolism in 20 response to treatment. Solute carriers (SLCs) play a key role in metabolic reprogramming 21 by transporting sugars, amino acids, and other nutrients and regulating their abundance 22 within the cell and its subcellular organelles. We found 109 SLC mRNAs to be 23 differentially expressed between endocrine sensitive and resistant breast cancer cells. In 24 univariate analyses, 55 of these SLCs were associated with poor outcome in ER+ breast 25 cancer patients. Data from TMT and SILAC studies then led us to focus on SLC7A5 26 (LAT1). In complex with SLC3A2 (CD98), LAT1 is the primary transporter of large, neutral 27 amino acids including leucine and tyrosine. LAT1 expression is estrogen-regulated in 28 endocrine sensitive cells but this regulation is lost in resistant cells. Pharmacologic 29 inhibition or genetic depletion of LAT1 each suppressed growth in two models of 30 endocrine resistant breast cancer. Autophagy was activated with LAT1 inhibition, but cells 31 failed to degrade p62 showing that flux was blocked. Overexpression of the LAT1 cDNA 32 increased protein synthesis and high LAT1 expression correlated with poor disease-free 33 survival in ER+ breast cancer patients. This study uncovers a novel LAT1 mediated 34 adaptive response that contributes to the development of endocrine resistance. Blocking 35 LAT1 function may offer a new avenue for effective therapeutic intervention against 36 endocrine resistant ER+ breast cancers.
harvest, cells were washed with 1X PBS and rocked in 200 µL crystal violet solution (2.5 142 g crystal violet, 125 mL methanol, 375 mL water) for 30 minutes. Plates were rinsed in 143 deionized water and allowed to air-dry for 48 hours. Once all time points were collected, 144 citrate buffer was used to extract dye. Analysis of the intensity of staining, which directly 145 reflects cell number, was then assessed at 570 nm using a VMax kinetic microplate reader 146 (Molecular Devices Corp., Menlo Park, CA) 13, 32 .
147
Western blotting: Total protein was collected in radioimmunoprecipitation buffer (RIPA) 148 with PhosSTOP (Roche Diagnostics, Mannheim, Germany) and Complete Mini protease 149 inhibitor cocktail tablets (EMD Chemicals Inc. San Diego, CA). Quantification was done 150 using Pierce BCA protein assay (Thermo Fischer Scientific) and 20 µg were separated 151 by NuPAGE 4-12% Bis-Tris gel (Invitrogen). Primary antibodies used were LAT1 (Cat 152 #5347S, 1:1,000; Cell Signaling), CD98 (Cat# sc-376815, 1:1,000; Santa Cruz), ER alpha 153 (Cat# sc-543, 1:1,000; Santa Cruz Biotechnology), and β-Actin (Cat# 66009-1-Ig, 154 1:10,000; Protein Tech). Secondary antibodies used were Anti-rabbit IgG, HRP-linked 155 Antibody #7074 (1:2,000; Cell Signaling) and Anti-mouse IgG, HRP-linked Antibody 156 #7076 (1:2,000; Cell Signaling).
157
RNA isolation and qRT-PCR: RNA was isolated using the trizol reagent (Invitrogen, CA, CAG GAA GCG A). Analysis of the data followed the delta-delta CT method 33 .
171
Immunofluorescence staining: 10,000-50,000 cells were plated onto glass cover slips 172 24 hours before treatment. Immunofluorescence experiments were performed on cells 173 after 24 hours of either vehicle or 1 nM 17β-estradiol exposure. Cells were fixed with PBS 174 containing 3.2% paraformaldehyde (Cat# 15714, PA, USA) with 0.2% Triton X-100 (Cat# 175 T8532-500mL, SIGMA, MA, USA) for 5 minutes before being washed with PBS. Cells 176 were incubated in methanol in the -20 o C for 20 minutes. Cells were washed again before 177 being exposed to primary antibody in the presence of an antibody block containing 10% 178 goat serum. Primary antibodies were as described in the western blotting protocol above; 179 the concentration of LAT1 was 1:100 and was 1:50 for CD98. Secondary antibodies used 180 were Alexa Fluor 594 anti-rabbit (Cat# A-11012, Life Technologies) and Alexa Fluor 488, Resource then collected for protein or analyzed for cell cycle analysis. Data were acquired 186 using flow cytometry (BD LSRFortessa; BD Biosciences) and data analysis was 187 performed using FCS express 6 software (De Novo Software, Glendale, CA) 188 Clinical correlation analyses: We studied only data from invasive ER+ breast cancers 189 that received at least one endocrine therapy (tamoxifen) from the following publicly 190 available datasets (GSE2990 34 , GSE6532-a 35 , GSE6532-p 35 , GSE9195 36 ). Data were (GSE46222) was also analyzed and the results are shown in Table 1 . (Table 1) . When mapped onto the proteomic data 207 (TMT and SILAC), three SLCs: SLC2A1, SLC3A2, and SLC7A5 (Table 2) were each 208 upregulated at least 1.5 fold. We had previously studied SLC2A1 (GLUT1) and found that 209 glucose and glutamine uptake are regulated by MYC 13 . Here, we have focused on 210 SLC7A5 (LAT1) and its protein partner SLC3A2 (CD98) to determine their role in 211 endocrine therapy resistance.
212
LAT1 is regulated by estrogen and upregulated in endocrine therapy sensitive 213 cells: 214 We used MCF7, LCC1, LCC9, 15 T47D:A18, T47D:C42, and T47D:4HT 17 cells as models 215 to study the role of LAT1 in endocrine resistance. From the three analyses, we found that 216 LAT1 was significantly upregulated in the endocrine resistant LCC9 compared with 217 endocrine sensitive LCC1 cells. Previously, LAT1 (SLC7A5) mRNA has been reported 218 to be induced by estrogen in MCF7 cells 40 . We confirmed this observation for LAT1 219 protein in MCF7 cells ( Figure 1A ) and found a similar induction in LCC1 and T47D:A18 220 cells ( Figure 1A&B ). Endocrine resistant LCC9, T47D:4HT, and T47D:C42 cells 221 expressed significantly higher basal levels of total LAT1 protein than their respective 222 (sensitive) parental cell lines. Since these data infer estrogen regulation of LAT1 by the Figure 5A and 5B respectively).
286
Fluorescence imaging of the GFP tag ( Figure 5C ) also confirmed plasmid expression.
287
Puromycin treatment of transfected cells showed an increase in global protein translation 288 ( Figure 5D ). In addition to increased global translation in the sensitive cells, we observed 289 an increased trend for cells to be in S phase in both MCF7 and LCC1 cells ( Figure 5E ).
290

Autophagy increases with LAT1 inhibition 291
Increased autophagy is a feature of endocrine resistant cells 12,47 that may cooperate with was significantly increased ( Figure 6C and D). These data imply either an increased rate 304 of GRP78 protein turnover or a delay in increasing mRNA translation; determining the 305 precise mechanism is beyond the scope of the current study. 
